BioSpace News Archive

AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS) today presented new clinical and pre-clinical data for ABP-450 in treating cervical dystonia (CD) and posttraumatic stress disorder (PTSD) at TOXINS 2024, a leading conference held by the International Neurotoxin Association (INA) from January 17th - 20th at the Estrel Berlin in Berlin, Germany.

Living in a high-income neighborhood, having private health insurance, and being older are tied to an increased likelihood that life support will be withdrawn for people who have suffered severe bleeding in the brain, a new study shows.

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced the closing of a comprehensive, non- dilutive definitive credit agreement with Ares Management Credit funds for $350 million of senior secured, interest-only, credit facilities with 6-year maturities.

Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., and Generics (U.K.) Ltd. in a hearing before the Opposition Division of the European Patent Office (EPO).

Kane Biotech Inc. announces that on February 20, 2024, the Company will hold a special meeting of its shareholders to consider the election of Dr. Robert Huizinga as an additional director of the Company.

GH Research PLC (Nasdaq: GHRS) today announced that it recently received a communication from the European Patent Office (EPO) that it has been granted a patent with claims directed to mebufotenin (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in treating patients diagnosed with major depressive disorder (MDD) and treatment-resistant forms of MDD, such as treatment-resistant depression (TRD).

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap.

Myriad Genetics, Inc. announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed.

Deciphera Pharmaceuticals, Inc. today announced the presentation of new long-term results from the INTRIGUE Phase 3 clinical study comparing QINLOCK® (ripretinib) versus sunitinib in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib.

Optinose today announced peer-reviewed publication of results from both ReOpen1 and ReOpen2 in the Journal of Allergy and Clinical Immunology: In Practice1.